Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs T Rowe Price Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while T Rowe Price Group Inc trades at $113.73 (market cap $25.40B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.39% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TROW | |
|---|---|---|
Market Cap | $39.89B | $25.40B |
Sector | Health | Financials |
52-Week High | $491.22 | $120.16 |
52-Week Low | $278.09 | $86.19 |
Enterprise Value | $38.15B | $22.11B |
Dividend Yield | — | 4.39% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
